Search
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreHighlights of Past EHA (HOPE) Latin America (LA) 2019
Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs:
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)
EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…
Hans Erik Johnsen 1948-2018
On May 17, 2018, just after his 70th birthday, Hans Erik Johnsen passed away. Hans Johnsen was Professor of Clinical Hematology at the Department of Hematology at Aalborg University in Denmark.
Read moreTransfusion
The aim of this SWG is to strengthen and invigorate European research in transfusion, to foster new networks and collaborations, with the ultimate goal of optomisingtransfusion practice in Europe based on scientific evidence.
Read moreEHA Congratulates EHA Kick-Off Grant 2021 Winners
The Hague, January 3, 2022 –EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2021 after a rigorous selection process.
Read moreClinical trials
The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.
Read moreEHA Innovation Grant
The call for applications is closed. The EHA Innovation Grant is intended to encourage and support the creation of consortia and the generation of preliminary data to facilitate applying for larger funding opportunities.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- »